- Details
- Press Release
Sabinsa has been granted U.S. patent US10166261 for a method of managing dementia and dementia-related sleep disorders presented as symptoms of major depressive disorder (MDD) in humans associated with Irritable Bowel Syndrome (IBS) by administering Bacillus coagulans MTCC 5856 (LactoSpore®) at a dose of 2 billion colony forming units per day. The patent also claims LactoSpore’s ability to reduce serum myeloperoxidase, an essential biochemical marker of MDD.
- Details
- Press Release
Reduction of TMAO Formation Found, Novel Findings for Heart Health
A new study collaboratively published by Sabinsa researchers and academic scientists from Taiwan and China, demonstrates that Sabinsa’s sustainably-sourced pterostilbene attenuates Trimethylamine-N-oxide (TMAO) formation and decreases vascular inflammation, confirming cardioprotective properties. The animal study findings were published online in the article Prevention of Vascular Inflammation by Pterostilbene via Trimethylamine-N-Oxide Reduction and Mechanism of Microbiota Regulation in Molecular Nutrition and Food Research (Volume 63, Issue 20).
- Details
- Press Release
Award Presented During the Economic Times Business Leaders 2019 Award Ceremony
Sabinsa’s parent company Sami Labs Limited received The Economic Times’ Business Leaders 2019 Award for Most Trusted Nutraceutical Company in a ceremony held in Mumbai, India last month. The Economic Times, is the leading financial daily in India and among the world’s top three daily newspapers.
- Details
- Press Release
The Sami-Sabinsa Group’s export success was recently recognized by the Visveshwaraiah Trade Promotion Centre (VTPC), under the auspices of the Industries Department, Government of Karnataka, India. Sabinsa’s parent company Sami Labs Limited received three Export Excellence Awards for the financial year 2016-17.
- Details
- Press Release
Sabinsa’s Curcumin C3 Complex®, the #1 researched curcumin ingredient on the market, was used in a new published study on Non-Alcoholic Fatty Liver Disease (NAFLD), the most common chronic liver condition for which no approved pharmaceutical treatments exist.